Buy Thymosin Alpha-1 Research Peptide

What is Thymosin Alpha-1?

Thymosin Alpha-1 is a natural 28-amino-acid peptide first found in calf thymus. It is studied in laboratory research for its effects on immune signaling, including toll-like receptor activation and T-cell pathways.

• A 28-amino-acid peptide made naturally in thymus tissue
• Studied for its effects on toll-like receptor signaling and immune-cell activation
• Studied in laboratory immune research including cytokine signaling
• Activates innate immune signaling in lab research models

For research use only. Not approved for human therapeutic use.

Thymosin Alpha-1 (CAS 62304-98-7), also known as Thymalfasin, is a synthetic 28-amino acid peptide with the molecular formula C129H215N33O55 and a molecular weight of 3108.34 g/mol. Defined by the amino acid sequence Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn-OH, Thymalfasin features a characteristic N-terminal acetylation and is the most extensively characterised individual peptide within the thymosin family. Produced via solid-phase peptide synthesis, Thymalfasin signals through Toll-like receptors (TLRs) and is associated with T-cell maturation and innate immune signalling pathways in preclinical immunology research.

Thymosin Alpha-1 has been extensively investigated as one of the most widely studied thymic peptides in preclinical and translational immunology. Published in vitro studies in dendritic cell preparations have examined Thymalfasin’s interaction with Toll-like receptors (specifically TLR2 and TLR9) and downstream MyD88-dependent signalling cascades, documenting dendritic cell activation and Th1 immune polarisation as primary signalling outputs of Thymosin Alpha-1-mediated TLR engagement and characterising IL-12 production and IFN-γ secretion as downstream readouts of receptor-mediated dendritic cell maturation under controlled conditions [1]. In vivo mouse studies have investigated Thymalfasin/Thymosin α1 in immunological challenge models, including murine cytomegalovirus infection and cyclophosphamide-conditioned tumour models. These studies documented antiviral immune activation through TLR9/MyD88/IRF7-dependent pathways and IFN-α/IFN-γ responses, as well as dependence on CD4/CD8 T-cell and NK-cell compartments in cyclophosphamide-treated mice, consistent with Thymalfasin as an immunomodulatory agent acting across innate and adaptive immune responses under conditions of immune challenge [2][3], making Thymosin Alpha-1 a key reference compound in thymic peptide research examining TLR-mediated innate immune signalling and T-cell maturation in preclinical immunology models.

Thymosin Alpha-1 is produced to research-grade standards and independently verified by third-party HPLC and MS-UPLC analysis before dispatch. Vials are vacuum sealed and stored in a temperature controlled, monitored cold storage system. Certificates of Analysis are available on request.

Sold strictly for in vitro research purposes only. Not for human consumption. Intended for use by qualified researchers in laboratory settings only.

References

1Romani L, Bistoni F, Gaziano R, Bozza S, Montagnoli C, Perruccio K, et al. Thymosin alpha 1 activates dendritic cells for antifungal Th1 resistance through toll-like receptor signaling. Blood. 2004 Jun 1;103(11):4232–9. .PubMed PMID: 149828772Bozza S, Gaziano R, Bonifazi P, Zelante T, Pitzurra L, Montagnoli C, et al. Thymosin alpha1 activates the TLR9/MyD88/IRF7-dependent murine cytomegalovirus sensing for induction of anti-viral responses in vivo. Int Immunol. 2007 Nov;19(11):1261–70. .PubMed PMID: 178046873Mastino A, Favalli C, Grelli S, Rasi G, Pica F, Goldstein AL, et al. Combination therapy with thymosin alpha 1 potentiates the anti-tumor activity of interleukin-2 with cyclophosphamide in the treatment of the Lewis lung carcinoma in mice. Int J Cancer. 1992 Feb 1;50(3):493–9. .PubMed PMID: 1735618

Scientific Review

Dr. Martina Rossi, PhD

Scientific Contributor and Reviewer

Reviewed for scientific accuracy, 14 June 2026

View credentials →

Thymosin Alpha-1 (CAS 62304-98-7), also known as Thymalfasin, is a synthetic 28-amino acid peptide with the molecular formula C129H215N33O55 and a molecular weight of 3108.34 g/mol. Defined by the amino acid sequence Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn-OH, Thymalfasin features a characteristic N-terminal acetylation and is the most extensively characterised individual peptide within the thymosin family. Produced via solid-phase peptide synthesis, Thymalfasin signals through Toll-like receptors (TLRs) and is associated with T-cell maturation and innate immune signalling pathways in preclinical immunology research.

Thymosin Alpha-1 has been extensively investigated as one of the most widely studied thymic peptides in preclinical and translational immunology. Published in vitro studies in dendritic cell preparations have examined Thymalfasin’s interaction with Toll-like receptors (specifically TLR2 and TLR9) and downstream MyD88-dependent signalling cascades, documenting dendritic cell activation and Th1 immune polarisation as primary signalling outputs of Thymosin Alpha-1-mediated TLR engagement and characterising IL-12 production and IFN-γ secretion as downstream readouts of receptor-mediated dendritic cell maturation under controlled conditions [1]. In vivo mouse studies have investigated Thymalfasin/Thymosin α1 in immunological challenge models, including murine cytomegalovirus infection and cyclophosphamide-conditioned tumour models. These studies documented antiviral immune activation through TLR9/MyD88/IRF7-dependent pathways and IFN-α/IFN-γ responses, as well as dependence on CD4/CD8 T-cell and NK-cell compartments in cyclophosphamide-treated mice, consistent with Thymalfasin as an immunomodulatory agent acting across innate and adaptive immune responses under conditions of immune challenge [2][3], making Thymosin Alpha-1 a key reference compound in thymic peptide research examining TLR-mediated innate immune signalling and T-cell maturation in preclinical immunology models.

Thymosin Alpha-1 is produced to research-grade standards and independently verified by third-party HPLC and MS-UPLC analysis before dispatch. Vials are vacuum sealed and stored in a temperature controlled, monitored cold storage system. Certificates of Analysis are available on request.

Sold strictly for in vitro research purposes only. Not for human consumption. Intended for use by qualified researchers in laboratory settings only.

References

1Romani L, Bistoni F, Gaziano R, Bozza S, Montagnoli C, Perruccio K, et al. Thymosin alpha 1 activates dendritic cells for antifungal Th1 resistance through toll-like receptor signaling. Blood. 2004 Jun 1;103(11):4232–9. .PubMed PMID: 149828772Bozza S, Gaziano R, Bonifazi P, Zelante T, Pitzurra L, Montagnoli C, et al. Thymosin alpha1 activates the TLR9/MyD88/IRF7-dependent murine cytomegalovirus sensing for induction of anti-viral responses in vivo. Int Immunol. 2007 Nov;19(11):1261–70. .PubMed PMID: 178046873Mastino A, Favalli C, Grelli S, Rasi G, Pica F, Goldstein AL, et al. Combination therapy with thymosin alpha 1 potentiates the anti-tumor activity of interleukin-2 with cyclophosphamide in the treatment of the Lewis lung carcinoma in mice. Int J Cancer. 1992 Feb 1;50(3):493–9. .PubMed PMID: 1735618

Scientific Review

Dr. Martina Rossi, PhD

Scientific Contributor and Reviewer

Reviewed for scientific accuracy, 14 June 2026

View credentials →CAS Number62304-98-7Molecular Weight3,108.31 g/molPurity≥98%Physical FormLyophilised PowderManufacturingManufactured in an ISO9001 Certified LaboratoryTestingHPLC + MS-UPLCSKUTA1

Lyophilised powder: store at -20 °C or below, away from light and moisture. Once reconstituted in an appropriate laboratory diluent (e.g. sterile water, PBS, or assay buffer), store at 2–8 °C and use within the validated period for your protocol. Do not refreeze.

Thymosin Alpha-1 (CAS 62304-98-7), also known as Thymalfasin, is a synthetic 28-amino acid peptide with the molecular formula C129H215N33O55 and a molecular weight of 3108.34 g/mol. Defined by the amino acid sequence Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn-OH, Thymalfasin features a characteristic N-terminal acetylation and is the most extensively characterised individual peptide within the thymosin family. Produced via solid-phase peptide synthesis, Thymalfasin signals through Toll-like receptors (TLRs) and is associated with T-cell maturation and innate immune signalling pathways in preclinical immunology research.

Thymosin Alpha-1 has been extensively investigated as one of the most widely studied thymic peptides in preclinical and translational immunology. Published in vitro studies in dendritic cell preparations have examined Thymalfasin’s interaction with Toll-like receptors (specifically TLR2 and TLR9) and downstream MyD88-dependent signalling cascades, documenting dendritic cell activation and Th1 immune polarisation as primary signalling outputs of Thymosin Alpha-1-mediated TLR engagement and characterising IL-12 production and IFN-γ secretion as downstream readouts of receptor-mediated dendritic cell maturation under controlled conditions [1]. In vivo mouse studies have investigated Thymalfasin/Thymosin α1 in immunological challenge models, including murine cytomegalovirus infection and cyclophosphamide-conditioned tumour models. These studies documented antiviral immune activation through TLR9/MyD88/IRF7-dependent pathways and IFN-α/IFN-γ responses, as well as dependence on CD4/CD8 T-cell and NK-cell compartments in cyclophosphamide-treated mice, consistent with Thymalfasin as an immunomodulatory agent acting across innate and adaptive immune responses under conditions of immune challenge [2][3], making Thymosin Alpha-1 a key reference compound in thymic peptide research examining TLR-mediated innate immune signalling and T-cell maturation in preclinical immunology models.

Thymosin Alpha-1 is produced to research-grade standards and independently verified by third-party HPLC and MS-UPLC analysis before dispatch. Vials are vacuum sealed and stored in a temperature controlled, monitored cold storage system. Certificates of Analysis are available on request.

Sold strictly for in vitro research purposes only. Not for human consumption. Intended for use by qualified researchers in laboratory settings only.

References

1Romani L, Bistoni F, Gaziano R, Bozza S, Montagnoli C, Perruccio K, et al. Thymosin alpha 1 activates dendritic cells for antifungal Th1 resistance through toll-like receptor signaling. Blood. 2004 Jun 1;103(11):4232–9. .PubMed PMID: 149828772Bozza S, Gaziano R, Bonifazi P, Zelante T, Pitzurra L, Montagnoli C, et al. Thymosin alpha1 activates the TLR9/MyD88/IRF7-dependent murine cytomegalovirus sensing for induction of anti-viral responses in vivo. Int Immunol. 2007 Nov;19(11):1261–70. .PubMed PMID: 178046873Mastino A, Favalli C, Grelli S, Rasi G, Pica F, Goldstein AL, et al. Combination therapy with thymosin alpha 1 potentiates the anti-tumor activity of interleukin-2 with cyclophosphamide in the treatment of the Lewis lung carcinoma in mice. Int J Cancer. 1992 Feb 1;50(3):493–9. .PubMed PMID: 1735618

Scientific Review

Dr. Martina Rossi, PhD

Scientific Contributor and Reviewer

Reviewed for scientific accuracy, 14 June 2026

View credentials →CAS Number62304-98-7Molecular Weight3,108.31 g/molPurity≥98%Physical FormLyophilised PowderManufacturingManufactured in an ISO9001 Certified LaboratoryTestingHPLC + MS-UPLCSKUTA1

Lyophilised powder: store at -20 °C or below, away from light and moisture. Once reconstituted in an appropriate laboratory diluent (e.g. sterile water, PBS, or assay buffer), store at 2–8 °C and use within the validated period for your protocol. Do not refreeze.